Business / Investing

Add as a preferred source on Google

Jubilant Pharmova Q2 PAT Falls 74% as SPECT Shortage, Montreal Costs Pressure Margins

Revenue rose 21%, while a Nov. 17 NDTV Profit report said Nirmal Bang raised its target price.

Updated 2 min read
Workers inspect sterile injectable vials on a production line at a pharmaceutical facility in Montreal, Canada (AI-generated image / EconoTimes)
Workers inspect sterile injectable vials on a production line at a pharmaceutical facility in Montreal, Canada (AI-generated image / EconoTimes)

Jubilant Pharmova’s second-quarter profit after tax fell 74% to Rs 31 crore despite 21% sales growth, highlighting margin pressure as its U.S. Spokane operation reported higher revenue.

Revenue reached Rs 2,370 crore. EBITDA declined 27% to Rs 255 crore, and the EBITDA margin narrowed to 10.7% from 17.8% a year earlier. The company said reduced availability of high-margin SPECT products and added remediation work at its Montreal contract-manufacturing site weighed on EBITDA margins. It also cited lower operating profitability and higher depreciation as factors behind lower PAT margins.

Montreal’s production restart enabled the sale of a commercial SPECT product, the company said. Jubilant expects supply to improve in the second half of FY27.

A Nov. 17 NDTV Profit report said Nirmal Bang Institutional Research used a 25 times price-to-earnings multiple on its September 2028 estimates. The report said the brokerage maintained its Buy rating and raised its target price to Rs 1,266 from Rs 1,261. NDTV Profit reported that the brokerage’s H2 FY27 margin outlook depended on stronger SPECT availability, Montreal losses easing from their H1 pace and higher plant volumes. The outlet also said Nirmal Bang warned that further supply delays could postpone the recovery until FY28.

Revenue from Jubilant’s Spokane operation in the United States rose 36% to Rs 521 crore. The company’s CDMO sterile-injectables business grew 33% to Rs 522 crore, which it attributed to additional Line 3 revenue. Jubilant said media fills for Line 4 were complete and expects technology-transfer programs to start by the end of Q4 FY27 and continue into FY28.

The company has a proposed investment of more than US$60 million underway for six PET manufacturing sites, which it expects to be operational in FY28. It also expects to commercialize two diagnostic products in H2 FY28.

Related articles

View all